Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma

Leukemia Research

Volumn 34, Issue 7, 2010, Pages

  Seker, Mesut ^a   Ustaalioĝlu, Bala Basak Oven ^a   Bilici, Ahmet ^a   Yildirim, Mahmut Emre ^a   Kefeli, Umut ^a   Barisik, Nagehan Ozdemir ^a   Tamer, Ismet ^a   Gumus, Mahmut ^a  

^a Dr Lutfi Kirdar Education and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD20 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LAMIVUDINE; RITUXIMAB; VIRUS DNA;

ADULT; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LIVER FUNCTION TEST; MALE; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; PRIMARY CUTANEOUS MARGINAL ZONE B CELL LYMPHOMA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN NODULE;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOPHENOTYPING; LAMIVUDINE; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE INHIBITORS; SKIN NEOPLASMS;

EID: 77953022194     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.02.013     Document Type: Letter

References (23)

1. Willemze R., Kerl H., Sterry W., Berti E., Cerroni L., Chimenti S., et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997, 90:354-371.
2. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
3. Zinzani P.L., Quaglino P., Pimpinelli N., Berti E., Baliva G., Rupoli S., et al. Italian study group for cutaneous lymphomas prognostic factors in primary cutaneous B-cell lymphoma. J Clin Oncol 2006, 24:1376-1382.
4. Rijlaarsdam J.U., van der Putte S.C., Berti E., Kerl H., Rieger E., Toonstra J., et al. Cutaneous immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993, 23:117-125.
5. Gronbaek K., Ralfkiaer E., Kalla J., Skovgaard G.L., Guldberg P. Infrequent somatic Fas mutations but no evidence of Bcl-10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma. J Pathol 2003, 201:134-140.
6. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol 2006, 16:425-431.
7. Smith B.D., Glusac E.J., McNiff J.M., Smith G.L., Heald P.W., Cooper D.L.., et al. Primary cutaneous B-cell lymphomas treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 2004, 22:634-639.
8. Kirova Y.M., Piedbois Y., Le Bourgeois J.P. Radiotherapy in the management of cutaneous B-cell lymphoma: our experience in 25 cases. Radiother Oncol 1999, 52:15-18.
9. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
10. Valencak J., Weihsengruber F., Rappersberger K., Trautinger F., Chott A., Streubel B., et al. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Ann Oncol 2009, 20:326-330.
11. Morales A.V., Advani R., Horwitz S.M., Riaz N., Reddy S., Hoppe R.T., et al. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol 2008, 59:953-957.
12. Kerl K., Prins C., Saurat J.H., French L.E. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 2006, 155:1197-1200.
13. Gellrich S., Muche J.M., Wilks A., Jasch K.C., Voit C., Fischer T., et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation. Br J Dermatol 2005, 153:167-173.
14. Soda R., Costanzo A., Cantonetti M., Orlandi A., Bianchi L., Chimenti S. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001, 81:207-208.
15. Gellrich S., Muche J.M., Pelzer K., Audring H., Sterry W. Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients. Hautarzt 2001, 52:205-210. [German].
16. Salepci T., Seker M., Kurnaz E., Guler D.O., Bilici A., Dane F., et al. Conjunctival malt lymphoma successfully treated with single agent rituximab therapy. Leuk Res 2009, 33:e10-e13.
17. Seker M., Bilici A., Ustaalioglu B.O., Salman T., Sonmez B., Canpolat N.A., et al. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma. Leuk Res 2009, 33:e154-e156.
18. Ozguroglu M., Bilici A., Turna H., Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma. Med Oncol 2004, 21:67-72.
19. Tsutsumi Y., Kanamori H., Mori A., Tanaka J., Asaka M., Imamura M., et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005, 4:599-608.
20. Li Y.H., He Y.F., Jiang W.Q., Wang F.H., Lin X.B., Zhang L., et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006, 15(106):1320-1325.
21. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220. [review].
22. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005, 55:828-831.
23. Perceau G., Diris N., Estines O., Derancourt C., Lévy S., Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006, 155:1053-1056.